Asset profile
WD-1603
Small molecule
Evidence outlook · lead readout
NCT05036473 · Parkinson Disease
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT05036473: The study was randomized and double-blind, with three active-dose groups and a placebo comparator, but enrollment was small at 40 participants. Its primary endpoint was a clinical Parkinson’s disease rating measure; because results are not posted, it is not possible to determine whether the primary comparison was met.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.